Eli Lilly and Company $LLY Shares Sold by Opes Wealth Management LLC

Opes Wealth Management LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 72.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 417 shares of the company’s stock after selling 1,119 shares during the quarter. Opes Wealth Management LLC’s holdings in Eli Lilly and Company were worth $318,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after acquiring an additional 11,396 shares in the last quarter. Rede Wealth LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $487,000. Central Pacific Bank Trust Division grew its stake in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Cidel Asset Management Inc. increased its holdings in Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Finally, Oak Family Advisors LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $1,979,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Study finds stopping GLP‑1s raises heart attack, stroke and death risk — this supports chronic use of Lilly’s diabetes/obesity medicines, which can support long-term revenue and pricing resilience. Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Lilly is investing heavily in manufacturing capacity — $1.8B to update Indianapolis operations plus plans for a $3.5B Pennsylvania plant — which supports supply readiness as demand scales and could ease future bottlenecks. Lilly spending $1.8B to update Indianapolis manufacturing operations Eli Lilly’s road to Pennsylvania, details of new $3.5B plant, celebrated in the Lehigh Valley
• Neutral Sentiment: Opinion pieces weigh competitive dynamics—some bullish views argue Lilly remains a market leader and a buy alongside peers (Roche), highlighting structural growth; these are balanced takes rather than new data. Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I’d Buy Both)
• Neutral Sentiment: Technical/market commentary notes the stock is oversold after the pullback and approaching potential support levels—this frames a “buy‑the‑dip” debate but is not a fundamental catalyst. Stock Of The Day: Is The Eli Lilly Selloff Over?
• Negative Sentiment: HSBC downgraded LLY to “Reduce” (from Hold), cutting its price target to $850 and citing U.S. pricing pressure, intensifying competition (oral pills, rival GLP‑1s) and what it sees as overhyped obesity‑market assumptions—this is the primary driver of the day’s share weakness. Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why
• Negative Sentiment: Multiple analyst writeups and headlines highlight heightened rivalry (Novo Nordisk, Roche), mixed FDA signals around oral obesity pills and the risk that market share/pricing assumptions for tirzepatide products may be too optimistic—adding to near‑term downside risk. ‘Run for the Hills,’ Says Analyst About Eli Lilly Stock (LLY) Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

Eli Lilly and Company Price Performance

Shares of LLY opened at $916.88 on Thursday. The firm has a market cap of $866.28 billion, a price-to-earnings ratio of 39.95, a PEG ratio of 1.08 and a beta of 0.40. The stock has a 50 day moving average of $1,029.72 and a 200-day moving average of $955.25. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. CICC Research increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Finally, Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.